Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ACTRN12625000824460) titled 'AMLM26/T9 INTERCEPT A multi-arm trial for patients with acute myeloid leukemia investigating new treatments which target early relapse and changes in disease characteristics - PHI-101' on Aug. 1.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Safety/efficacy
Primary Sponsor: Australasian Leukaemia & Lymphoma Group
Condition:
Acute Myeloid Leukemia
Acute Myeloid Leukemia
Cancer - Leukaemia - Acute leukaemia
Intervention:
The ALLG AMLM26 INTERCEPT trial is an adaptive trial allowing th...